Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	SEK 0.3440	+1.18%	1,303,147
05/11/26	SEK 0.3400	+1.04%	1,873,186
04/11/26	SEK 0.3365	+0.30%	1,298,514
03/11/26	SEK 0.3355	-2.04%	3,811,487
02/11/26	SEK 0.3425	-3.39%	4,422,653

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Alzinova AB

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alzinova AB

Company calendar

Market Closed - Nasdaq Stockholm 04:00:00 07/11/26 am AEDT			5-day change	1st Jan Change
0.3440 ^SEK	+1.18%		-2.96%	-58.50%

06/11	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
03/11	Alzinova Seeks US Ethical Approval for Phase 2a Alzheimer's Vaccine Study	MT

Market Cap	109M 11M 9.87M 9.02M 8.23M 15.51M 1.03B 16M 43.35M 552M 41.3M 40.42M 1.74B	P/E 2026 *	-2.46x	P/E 2027 *	-1.27x
Enterprise Value	99.72M 10.09M 9.05M 8.27M 7.55M 14.23M 949M 14.68M 39.77M 506M 37.89M 37.07M 1.6B	EV / Sales 2026 *	3.18x	EV / Sales 2027 *	-
Free-Float	82.68%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

06/11	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
03/11	Alzinova Seeks US Ethical Approval for Phase 2a Alzheimer's Vaccine Study	MT
03/11	Alzinova submits ethics application for Phase 2a study in the US	FW
02/11	17 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
02/11	Alzinova submits updated documentation to FDA ahead of Phase 2a study	FW
21/10	Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study	MT
21/10	Alzinova selects seven U.S. trial sites ahead of phase IIa study	FW
21/10	Alzinova AB Finalises Selection Of Seven US Clinical Sites As ADVANCE Phase 2a Study Moves Toward First Participant Enrolment	CI
20/10	Alzinova carries out directed issue worth SEK 3.6m to Mangold	FW
15/10	Calendar Thursday October 15	FW
09/10	Alzinova AB Presents Latest Developments In ALZ-101 And Blood-Based Diagnostics At Redeye Neurology Day	CI
08/10	Redeye reiterates fair value of SEK 0.90 for Alzinova following rights issue	FW
08/10	Alzinova's rights issue subscribed to 86.2 percent, raises SEK 44m	FW

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08/10	Redeye reiterates fair value of SEK 0.90 for Alzinova following rights issue	FW
07/10	RX Securities reiterates Buy on Alzinova, cuts fair value to SEK 2.50	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW

02/11	Alzinova : takes further step toward Phase 2a ADVANCE study with submitted FDA amendment for ALZ-101	PU
09/10	Alzinova: Rights issue subscribed to 86.2%	AQ
09/10	Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day	AQ
08/10	Alzinova: Rights issue completed	AQ
08/10	Alzinova announces final outcome of the rights issue	AQ

1 day	+1.18%
1 week	-2.96%
Current month	-2.96%
1 month	-17.11%
3 months	-67.67%
6 months	-18.96%
Current year	-58.50%

1 week	0.32	0.36
1 month	0.32	0.49
Current year	0.32	1.61
1 year	0.32	2.07
3 years	0.32	4.62
5 years	0.32	7.74
10 years	0.32	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	65	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+1.18%	-2.96%	-75.14%	-85.99%	11M
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+63.79%	66.7B
ARGENX SE	+0.02%	+1.07%	+11.72%	+75.63%	56.88B
LONZA GROUP AG	-1.34%	+2.98%	+25.08%	+100.18%	56.53B
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+105.85%	46.49B
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+35.86%	44.8B
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+794.74%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+55.48%	35.35B
GENMAB A/S	-2.97%	-9.84%	+90.91%	+73.49%	33.29B
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+368.87%	25.1B
Average	+1.13%	+2.09%	+36.75%	+158.79%	40.67B
Weighted average by Cap.	+0.65%	+3.07%	+49.90%	+165.87%

	2026 *	2027 *
Net sales	31.35M 3.17M 2.85M 2.6M 2.37M 4.47M 298M 4.61M 12.5M 159M 11.91M 11.65M 502M	-
Net income	1.55M 157K 141K 129K 117K 221K 14.75M 228K 618K 7.87M 589K 576K 24.84M	-84M -8.5M -7.63M -6.97M -6.36M -11.99M -799M -12.36M -33.49M -426M -31.91M -31.23M -1.35B
Net Debt	-9M -911K -817K -747K -682K -1.28M -85.63M -1.32M -3.59M -45.69M -3.42M -3.35M -144M	-4M -405K -363K -332K -303K -571K -38.06M -589K -1.59M -20.31M -1.52M -1.49M -64.11M